Viking Therapeutics, Inc. VKTX
- VK2735 — Obesity Phase 3
- VK2735 — Type 2 Diabetes Phase 3
- VK2735 — Obesity Phase 2
GIP receptor (2 companies · 5 programs)
Companies with an active program directed at GIP receptor.
Protagonist Therapeutics, Inc PTGX
- PN-477 — Obesity Phase 1
- PN-458 — Obesity Preclinical